Pazopanib Hydrochloride Patent Expiration
Pazopanib Hydrochloride was first introduced by Novartis Pharmaceuticals Corp
Pazopanib Hydrochloride Patents
Given below is the list of patents protecting Pazopanib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Votrient | US7105530 | Pyrimidineamines as angiogenesis modulators |
Oct 19, 2023
(Expired) | Novartis |
| Votrient | US7262203 | Pyrimidineamines as angiogenesis modulators |
Dec 19, 2021
(Expired) | Novartis |
| Votrient | US8114885 | Chemical compounds |
Dec 19, 2021
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Pazopanib Hydrochloride's patents.
Latest Legal Activities on Pazopanib Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Pazopanib Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 18 Mar, 2024 | US8114885 |
| Maintenance Fee Reminder Mailed Critical | 02 Oct, 2023 | US8114885 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 02 Aug, 2019 | US8114885 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Feb, 2019 | US7262203 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 01 Mar, 2018 | US7105530 |
| Email Notification Critical | 05 Jun, 2015 | US8114885 |
| Change in Power of Attorney (May Include Associate POA) Critical | 05 Jun, 2015 | US8114885 |
| Correspondence Address Change Critical | 04 Jun, 2015 | US8114885 |
| Email Notification Critical | 04 Jun, 2015 | US7262203 |
| Change in Power of Attorney (May Include Associate POA) Critical | 04 Jun, 2015 | US7262203 |
Pazopanib Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Pazopanib Hydrochloride Generic API Manufacturers
Several generic applications have been filed for Pazopanib Hydrochloride. The first generic version for Pazopanib Hydrochloride was by Sun Pharmaceutical Industries Ltd and was approved on Oct 19, 2023. And the latest generic version is by Novugen Oncology Sdn Bhd and was approved on Apr 23, 2024.
Given below is the list of companies who have filed for Pazopanib Hydrochloride generic, along with the locations of their manufacturing plants worldwide.
1. APOTEX
Apotex Inc has filed for 1 generic for Pazopanib Hydrochloride. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 200MG BASE | tablet | Prescription | ORAL | AB | Oct 19, 2023 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||
| Canada |
| |||||||||||||
| India |
| |||||||||||||
2. NOVUGEN
Novugen Oncology Sdn Bhd has filed for 1 generic for Pazopanib Hydrochloride. Given below are the details of the strengths of this generic introduced by Novugen.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 200MG BASE | tablet | Prescription | ORAL | AB | Apr 23, 2024 |
3. SUN PHARM
Sun Pharmaceutical Industries Ltd has filed for 1 generic for Pazopanib Hydrochloride. Given below are the details of the strengths of this generic introduced by Sun Pharm.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 200MG BASE | tablet | Prescription | ORAL | AB | Oct 19, 2023 |
Manufacturing Plant Locations New
Sun Pharm's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Sun Pharm as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||||||||||||||
| India |
| |||||||||||||||||||||||||||||
4. TEVA PHARMS INC
Teva Pharmaceuticals Inc has filed for 1 generic for Pazopanib Hydrochloride. Given below are the details of the strengths of this generic introduced by Teva Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 200MG BASE | tablet | Prescription | ORAL | AB | Oct 19, 2023 |